← Back to Search

Noninvasive Brain Stimulation

ADHD for Attention Deficit Hyperactivity Disorder (ADHD)

N/A
Waitlist Available
Led By Joan Camprodon, MD, PhD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change before and after stimulation on each of the four visits, average of 2-6 weeks
Awards & highlights

Study Summary

This trial is testing whether a certain type of brain stimulation can help improve cognitive function, and whether different intensities and durations of stimulation have different effects.

Who is the study for?
This trial is for adults aged 18-55 with ADHD, diagnosed per DSM-5 criteria. Participants can be on non-stimulant meds if the dose has been stable for 4 weeks. Those on stimulants must stop them two days before each study visit under a doctor's guidance but may resume between visits.Check my eligibility
What is being tested?
The study tests how different doses of Transcranial Direct Current Stimulation (tDCS) to the left DLPFC affect cognitive and brain functions in people with ADHD. It looks at various current intensities, electric field strengths, and durations of stimulation.See study design
What are the potential side effects?
Potential side effects from tDCS include mild tingling or itching at the electrode site during application, fatigue, headache, nausea or discomfort. These are generally temporary and considered mild.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change before and after stimulation on each of the four visits, average of 2-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change before and after stimulation on each of the four visits, average of 2-6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Accuracy and Reaction Time in Attention and Working Memory
Secondary outcome measures
Electroencephalography

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
Car accident
2%
skin irritation
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Healthy ControlExperimental Treatment1 Intervention
Volunteers without Neuropsychiatric Disorders.
Group II: ADHDExperimental Treatment1 Intervention
Patients with ADHD.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,943 Previous Clinical Trials
13,200,885 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,435 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joan Camprodon, MD, PhD, MPHPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
880 Total Patients Enrolled
2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
720 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
~0 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top